Kevin S. Quackenbush

A phase II study of the gamma secretase inhibitor RO4929097 in patients with previously treated metastatic pancreatic adenocarcinoma

Ana De Jesus‐Acosta, Daniel A. Laheru, Anirban Maitra et al. · Investigational New Drugs · 2014 · 107 citations · Full text

Oncology, Pancreatic Cancer, Gastrointestinal Oncology +8

Potent antitumor activity of cabozantinib, a c‐<scp>MET</scp> and <scp>VEGFR</scp>2 inhibitor, in a colorectal cancer patient‐derived tumor explant model

Eun‐Kee Song, WM. Tai, Wells A. Messersmith et al. · International Journal of Cancer · 2014 · 60 citations · Full text

Tumor Biology, Tumor Explant Model, Oncology +15

A<i>NOTCH1</i>gene copy number gain is a prognostic indicator of worse survival and a predictive biomarker to a Notch1 targeting antibody in colorectal cancer

John J. Arcaroli, Wan‐Tien Tai, Ryan McWilliams et al. · International Journal of Cancer · 2015 · 45 citations · Full text

Tumor Biology, Advanced Crc, Tumor Heterogeneity +15

Cabozantinib Exhibits Potent Antitumor Activity in Colorectal Cancer Patient-Derived Tumor Xenograft Models via Autophagy and Signaling Mechanisms

Aaron J. Scott, John J. Arcaroli, Stacey M. Bagby et al. · Molecular Cancer Therapeutics · 2018 · 44 citations · Full text

Common PIK3CA Mutants and a Novel 3′ UTR Mutation Are Associated with Increased Sensitivity to Saracatinib

John J. Arcaroli, Kevin S. Quackenbush, Rebecca W. Powell et al. · Clinical Cancer Research · 2012 · 41 citations · Full text